---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical presentation - signs and symptoms. Topics: Neuroglycopenic symptoms: insulinoma, Autonomic symptoms: insulinoma, Timing of symptoms: fasting and postprandial hypoglycemia in insulinoma, Weight gain: insulinoma, and 5 further topics. 9 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Neuroglycopenic symptoms: insulinoma

> “neuroglycopenic symptoms such as confusion, visual disturbances, or seizures may also occur. The latter may cause patients to be misdiagnosed with a psychiatric or neurological disorder.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “96% of the patients had neuroglycopenic symptoms, and 77% had autonomic symptoms.”
> “The most common presenting symptoms were confusion (86%), drowsiness (58%), and excessive sweating (57%).”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “All patients had neuroglycopenic symptoms including confusion (83%) and personality change or bizarre behavior (64%).”
> “Amnesia for hypoglycemia was common (41%).”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-2"></a>

### Autonomic symptoms: insulinoma

> “In addition to the familiar hypoglycemic symptoms such as sweating, palpitations, nervousness, and feeling of hunger”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Autonomic symptoms (83%) were usually diaphoresis (69%) or tremulousness (24%).”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-3"></a>

### Timing of symptoms: fasting and postprandial hypoglycemia in insulinoma

> “Symptoms occur mainly in the fasting state, but up to 20% of patients also described postprandial symptoms”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Hypoglycemia was reported solely in the fasting state in 73%, the fasting and postprandial state in 21%, and exclusively postprandially in 6%.”

Source: [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)

> “The symptoms were usually progressive, provoked by fasting, and at worst, occurred daily or weekly.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “Food ingestion relieved symptoms in 71% of patients”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-4"></a>

### Weight gain: insulinoma

> “Weight gain was documented in 56% of the patients, of whom one-third gained weight more than 10 kilograms.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “39% reported weight gain.”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-5"></a>

### Tumor-related features: aggressive insulinoma

> “Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, and expression of ARX and alpha-1-antitrypsin, and decreased or absent immunohistochemical expression of insulin, PDX1, and GLP-1R.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Patients with malignant insulinoma were younger (median, 55.5 vs 66.0 years, P < .001) and less likely to be female (55.9% vs 65.3%, P = .061) than patients with benign insulinoma.”

Source: [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)

<a id="topic-2.2.1.6-6"></a>

### Adrenergic, cholinergic, and neuroglycopenic symptoms: tumor hyperinsulinism

> “The clinical manifestations of hypoglycemia are marked by adrenergic, cholinergic, and neuroglycopenic symptoms such as tremors, diaphoresis, confusion, seizures, and loss of consciousness, and may lead to life-threatening consequences”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.6-7"></a>

### Neuroglycopenic symptoms: NICTH

> “Loss of consciousness and confusion were the most common features in the patients, present in 26.7% and 21%, respectively.”
> “Weight loss, dizziness and weakness were other relatively less common features.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

> “In paraneoplastic hypoglycemia, the symptoms predominantly manifest as neuroglycopenic, affecting cognitive function and mental status significantly.”
> “On the other hand, in cases of recurrent or gradual-onset hypoglycemia, autonomic symptoms like sweating and tremors may be less noticeable.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

<a id="topic-2.2.1.6-8"></a>

### Tumor-related symptoms and order of presentation: NICTH

> “Hypoglycemic attack was the onset of disease in 31 of 65 cases (48%), but the tumor was revealed prior to the occurrence of hypoglycemia in 34 cases (52%).”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

> “Hypoglycaemia was identified as the presenting feature of NICT in 42% (98) of patients.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

> “Symptoms directly related to the tumor typically include weight loss, abdominal mass, pain, dyspnea, or incidental findings during routine examinations”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

> “In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="topic-2.2.1.6-9"></a>

### Metabolic and somatic features: hypokalemia and acromegaloid changes in NICTH

> “Twenty-five of 47 (53%) patients had decreased serum potassium levels.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

> “Rarely, markedly elevated IGF-2 levels produce somatic changes suggestive of acromegaly.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
